Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [917]
News [2633]
Articles [115]
Editorials [3]
Conferences [85]
elearning [27]
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
31 Jan 2024
What's new on ADCs in management of advanced NSCLC
Dr David Planchard - Institute Gustave Roussy, Villejuif, France
What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )
25 Jan 2024
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene...
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )
25 Jan 2024
ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023
Lung Cancer
Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India
Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )
6 Nov 2023
Innovative treatments for solid tumours – TTFields as a therapeutic modality
Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...
Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )
2 Nov 2023
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...
Prof Gerard Zalcman - Université de Paris, Paris, France
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )
27 Oct 2023
Selpercatinib benefit, with or without pembro, in first-line advanced RET...
Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong
Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC ( Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong )
23 Oct 2023
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )
22 Oct 2023
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC
Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )
21 Oct 2023
CheckMate-77T: Perioperative nivolumab benefit for NSCLC
Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA
CheckMate-77T: Perioperative nivolumab benefit for NSCLC ( Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA )
21 Oct 2023
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )
17 Oct 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation